RT Journal Article
T1 Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers
A1 Rodriguez, Marta
A1 Alonso-Alonso, Ruth
A1 Tomas-Roca, Laura
A1 Rodriguez-Pinilla, Socorro M.
A1 Manso-Alonso, Rebeca
A1 Cereceda, Laura
A1 Borregon, Jennifer
A1 Villaescusa, Teresa
A1 Cordoba, Raul
A1 Sanchez-Beato, Margarita
A1 Fernandez-Miranda, Ismael
A1 Betancor, Isabel
A1 Barcena, Carmen
A1 Garcia, Juan F.
A1 Mollejo, Manuela
A1 Garcia-Cosio, Monica
A1 Martin-Acosta, Paloma
A1 Climent, Fina
A1 Caballero, Dolores
A1 de la Fuente, Lorena
A1 Minguez, Pablo
A1 Kessler, Linda
A1 Scholz, Catherine
A1 Gualberto, Antonio
A1 Mondejar, Rufino
A1 Piris, Miguel A.
K1 Expression
K1 Survival
K1 Mutation
AB Peripheral T-cell lymphoma (PTCL) is a clinically aggressive disease, with a poor response to therapy and a low overall survival rate of approximately 30% after 5 years. We have analyzed a series of 105 cases with a diagnosis of PTCL using a customized NanoString platform (NanoString Technologies, Seattle, WA) that includes 208 genes associated with T-cell differentiation, oncogenes and tumor suppressor genes, deregulated pathways, and stromal cell subpopulations. A comparative analysis of the various histological types of PTCL (angioimmunoblastic T-cell lymphoma [AITL]; PTCL with T follicular helper [TFH] phenotype; PTCL not otherwise specified [NOS]) showed that specific sets of genes were associated with each of the diagnoses. These included TFH markers, cytotoxic markers, and genes whose expression was a surrogate for specific cellular subpopulations, including follicular dendritic cells, mast cells, and genes belonging to precise survival (NF-kappa B) and other pathways. Furthermore, the mutational profile was analyzed using a custom panel that targeted 62 genes in 76 cases distributed in AITL, PTCL-TFH, and PTCL-NOS. The main differences among the 3 nodal PTCL classes involved the RHOA(G)(17V) mutations (P
PB Elsevier
SN 2473-9529
YR 2021
FD 2021-12-20
LK https://hdl.handle.net/10668/25153
UL https://hdl.handle.net/10668/25153
LA en
DS RISalud
RD Apr 7, 2025